CAREERS AT. Profitable growth and financial stability are at the core of California Resources Corporation, and we work hard to be among the top performers in our industry.
The most common treatment for CLL is the chemotherapy drug fludarabine. This is given intravenously (through an IV) five days a week once a month, for four to six months. Although the schedule for fludarabine is rather inconvenient, it causes only modest side effects, such as fatigue.
Approved for Chronic Lymphocytic Leukemia (CLL) On February 18, 2010, the FDA granted approval to rituximab (RituxanÂ®, made by Genentech), in combination with fludarabine and cyclophosphamide (FC), for the treatment of both previously untreated and previously treated patients with chronic lymphocytic leukemia (CLL).